$IMNN
Imunon, Inc. Stock $imnn

$imnn Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000149315224011616 Filed on March 28, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue		$0.00
YoY Change		-100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin		$2.415M	$9.743M
YoY Change		-40.37%	-28.83%
% of Gross Profit
Research & Development	$3.294M	$3.553M	$11.29M
YoY Change	25.73%	18.43%	-3.8%
% of Gross Profit
Depreciation & Amortization	$70.30K	$71.64K	$248.2K
YoY Change	-63.51%	-67.44%	-66.08%
% of Gross Profit
Operating Expenses	$5.011M	$5.968M	$21.03M
YoY Change	-11.84%	-15.35%	-17.27%
Operating Profit	-$5.011M		-$21.03M
YoY Change	-11.84%		-15.61%
Interest Expense		$195.4K	$197.1K
YoY Change		95.43%	-96.08%
% of Operating Profit
Other Income/Expense, Net	$81.92K	-$396.3K	$235.1K
YoY Change	-11.99%	-107.34%	-101.87%
Pretax Income		-$6.169M	-$20.80M
YoY Change		-58.32%	-44.49%
Income Tax		-$1.280M	-$1.280M
% Of Pretax Income
Net Earnings	-$4.900M	-$4.888M	-$19.50M
YoY Change	-12.36%	-63.05%	-45.68%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.52		-$2.16
Diluted Earnings Per Share	-$0.52	-$0.52	-$2.16
COMMON SHARES
Basic Shares Outstanding	9.400M shares	9.399M shares	9.045M shares
Diluted Shares Outstanding	9.400M shares		9.045M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$9.809M	$15.70M	$15.70M
YoY Change	-68.54%	-52.07%	-54.17%
Cash & Equivalents	$2.347M	$5.839M	$5.839M
Short-Term Investments	$7.462M	$9.857M	$9.857M
Other Short-Term Assets	$2.285M	$2.545M	$2.545M
YoY Change	-18.08%	-8.45%	-8.45%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$12.09M	$18.24M	$18.24M
YoY Change	-66.71%	-50.91%	-50.9%
LONG-TERM ASSETS
Property, Plant & Equipment	$693.4K	$751.9K	$2.347M
YoY Change	24.72%	37.13%	235.28%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments		$0.00	$0.00
YoY Change		-100.0%	-100.0%
Other Assets	$1.537M	$2.925M	$1.330M
YoY Change	-70.54%	-53.36%	-17.88%
Total Long-Term Assets	$2.230M	$3.677M	$3.677M
YoY Change	-61.37%	-46.09%	-46.16%
TOTAL ASSETS
Total Short-Term Assets	$12.09M	$18.24M	$18.24M
Total Long-Term Assets	$2.230M	$3.677M	$3.677M
Total Assets	$14.32M	$21.92M	$21.92M
YoY Change	-65.98%	-50.16%	-50.16%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.358M	$3.515M	$3.515M
YoY Change	-40.66%	-1.99%	-2.08%
Accrued Expenses	$1.959M	$3.391M	$3.876M
YoY Change	-49.96%	-29.29%	-22.94%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due		$0.00	$0.00
YoY Change		-100.0%	-100.0%
Total Short-Term Liabilities	$4.817M	$7.391M	$7.391M
YoY Change	-53.76%	-26.36%	-26.38%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change	-100.0%	-100.0%	-100.0%
Other Long-Term Liabilities	$1.008M	$1.139M	$1.139M
YoY Change	-11.57%
Total Long-Term Liabilities	$1.008M	$1.139M	$1.139M
YoY Change	-80.0%	-75.29%	-75.29%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.817M	$7.391M	$7.391M
Total Long-Term Liabilities	$1.008M	$1.139M	$1.139M
Total Liabilities	$5.825M	$8.530M	$8.530M
YoY Change	-62.32%	-41.76%	-41.77%
SHAREHOLDERS EQUITY
Retained Earnings	-$393.1M	-$388.0M
YoY Change	5.04%	5.15%
Common Stock	$94.01K	$94.00K
YoY Change	3.34%	26.41%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$85.19K	$85.19K
YoY Change	0.0%	0.0%
Treasury Stock Shares
Shareholders Equity	$8.500M	$13.39M	$13.39M
YoY Change
Total Liabilities & Shareholders Equity	$14.32M	$21.92M	$21.92M
YoY Change	-65.98%	-50.16%	-50.16%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$4.900M	-$4.888M	-$19.50M
YoY Change	-12.36%	-63.05%	-45.68%
Depreciation, Depletion And Amortization	$70.30K	$71.64K	$248.2K
YoY Change	-63.51%	-67.44%	-66.08%
Cash From Operating Activities	-$5.900M	-$3.772M	-$19.00M
YoY Change	44.41%	-25.45%	-17.86%
INVESTING ACTIVITIES
Capital Expenditures	$11.76K	$0.00	$451.8K
YoY Change	-79.43%	-100.0%	68.69%
Acquisitions
YoY Change
Other Investing Activities	$2.394M	-$3.304M	$11.46M
YoY Change	312.77%	-69.38%	33.55%
Cash From Investing Activities	$2.382M	-$3.304M	$11.01M
YoY Change	358.76%	-69.5%	32.36%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$2.781M
YoY Change			-58.63%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		30.25K	-$3.639M
YoY Change		-93.12%	-154.12%
NET CHANGE
Cash From Operating Activities	-$5.900M	-3.772M	-$19.00M
Cash From Investing Activities	$2.382M	-3.304M	$11.01M
Cash From Financing Activities		30.25K	-$3.639M
Net Change In Cash	-$3.492M	-7.046M	-$11.65M
YoY Change	219.73%	-54.4%	44.0%
FREE CASH FLOW
Cash From Operating Activities	-$5.900M	-$3.772M	-$19.00M
Capital Expenditures	$11.76K	$0.00	$451.8K
Free Cash Flow	-$5.912M	-$3.772M	-$19.45M
YoY Change	42.7%	-26.18%	-16.87%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q4	us-gaap	Debt Securities Held To Maturity Accrued Interest After Allowance For Credit Loss DebtSecuritiesHeldToMaturityAccruedInterestAfterAllowanceForCreditLoss		usd
CY2023Q4	us-gaap	Other Short Term Investments OtherShortTermInvestments		usd
CY2023Q4	us-gaap	Other Long Term Investments OtherLongTermInvestments		usd
CY2023Q4	us-gaap	Notes Payable Current NotesPayableCurrent		usd
CY2023Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable		usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax		usd
CY2023	IMNN	Gain Loss From Change In Earnout Milestone Liability GainLossFromChangeInEarnoutMilestoneLiability		usd
CY2023	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill		usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2023	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized		usd
CY2023	IMNN	Gain Loss From Change In Earnout Milestone Liability GainLossFromChangeInEarnoutMilestoneLiability		usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2022	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs		usd
CY2023	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill		usd
CY2023	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets		usd
CY2023	us-gaap	Proceeds From Issuance Of Redeemable Convertible Preferred Stock ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock		usd
CY2023	us-gaap	Payments For Repurchase Of Redeemable Convertible Preferred Stock PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock		usd
CY2022	IMNN	Paymentoff Of Loan And Accrued Endofterm Fees PaymentoffOfLoanAndAccruedEndoftermFees		usd
CY2022	IMNN	Recognition Of Right Use Asset And Liability RecognitionOfRightUseAssetAndLiability		usd
CY2022	IMNN	Stock Issued During Period Value Reverse Stock Splits StockIssuedDuringPeriodValueReverseStockSplits		usd
CY2023Q4	IMNN	Available For Sale Securities Unrealized Loss Fair Value AvailableForSaleSecuritiesUnrealizedLossFairValue		usd
CY2023Q4	IMNN	Available For Sale Securities Unrealized Holding Losses Less Than Twelve Months AvailableForSaleSecuritiesUnrealizedHoldingLossesLessThanTwelveMonths		usd
CY2023Q4	us-gaap	Restricted Investments RestrictedInvestments		usd
CY2023Q4	us-gaap	Interest Payable Current InterestPayableCurrent		usd
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit		usd
CY2023	us-gaap	Deferred Federal State And Local Tax Expense Benefit DeferredFederalStateAndLocalTaxExpenseBenefit		usd
CY2022	us-gaap	Deferred Federal State And Local Tax Expense Benefit DeferredFederalStateAndLocalTaxExpenseBenefit		usd
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit		usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit		usd
CY2022	IMNN	Effective Income Tax Rate Reconciliation Time Up EffectiveIncomeTaxRateReconciliationTimeUp		pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments		pure
CY2022Q4	IMNN	Deferred Tax Assets Legal Act DeferredTaxAssetsLegalAct		usd
CY2022Q4	IMNN	Earnout Milestone Liability EarnoutMilestoneLiability		usd
CY2023Q4	IMNN	Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue		usd
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-15911
CY2023	dei	Entity Registrant Name EntityRegistrantName	IMUNON, INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	52-1256615
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	997 LENOX DRIVE
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	SUITE 100
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	LAWRENCEVILLE
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	08648
CY2023	dei	City Area Code CityAreaCode	(609)
CY2023	dei	Local Phone Number LocalPhoneNumber	896-9100
CY2023	dei	Security12b Title Security12bTitle	Common Stock, Par Value $0.01 Per Share
CY2023	dei	Trading Symbol TradingSymbol	IMNN
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	11900000	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	9399789	shares
CY2023	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023	dei	Auditor Name AuditorName	WithumSmith+Brown, PC
CY2023	dei	Auditor Location AuditorLocation	East Brunswick, New Jersey
CY2023	dei	Auditor Firm AuditorFirmId	100
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5838566	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11492841	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	9857087	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	21254485	usd
CY2022Q4	us-gaap	Debt Securities Held To Maturity Accrued Interest After Allowance For Credit Loss DebtSecuritiesHeldToMaturityAccruedInterestAfterAllowanceForCreditLoss	128932	usd
CY2022Q4	us-gaap	Other Short Term Investments OtherShortTermInvestments	1500000	usd
CY2023Q4	us-gaap	Grants Receivable Current GrantsReceivableCurrent	2545051	usd
CY2022Q4	us-gaap	Grants Receivable Current GrantsReceivableCurrent	2403433	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	18240704	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	36779691	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	751906	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	548301	usd
CY2022Q4	us-gaap	Other Long Term Investments OtherLongTermInvestments	4500000	usd
CY2023Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	1280385	usd
CY2022Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	1567026	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1595074	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	155876	usd
CY2023Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	50000	usd
CY2022Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	425000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2925459	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	6647902	usd
CY2023Q4	us-gaap	Assets Assets	21918069	usd
CY2022Q4	us-gaap	Assets Assets	43975894	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3515192	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3586623	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3390521	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4794936	usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	1424774	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	485421	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	230749	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	7391134	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	10037082	usd
CY2022Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	4610946	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1139293	usd
CY2023Q4	us-gaap	Liabilities Liabilities	8530427	usd
CY2022Q4	us-gaap	Liabilities Liabilities	14648028	usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	100000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	100000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	112500000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	112500000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	9399811	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	7436219	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	9399789	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	7436197	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	93998	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	74362	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	401500838	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	397980023	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	60796	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	26494	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-388182802	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-368667825	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-35863766	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-19514977	usd
CY2023Q4	us-gaap	Stockholders Equity Before Treasury Stock StockholdersEquityBeforeTreasuryStock	13472830	usd
CY2022Q4	us-gaap	Stockholders Equity Before Treasury Stock StockholdersEquityBeforeTreasuryStock	29413054	usd
CY2023Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	22	shares
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	22	shares
CY2023Q4	us-gaap	Treasury Stock Value TreasuryStockValue	85188	usd
CY2022Q4	us-gaap	Treasury Stock Value TreasuryStockValue	85188	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	13387642	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	29327866	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	21918069	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	43975894	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	500000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11287691	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11733666	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9742739	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	13687899	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	21030430	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	25421565	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-21030430	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-24921565	usd
CY2022	IMNN	Gain Loss From Change In Earnout Milestone Liability GainLossFromChangeInEarnoutMilestoneLiability	5396000	usd
CY2022	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	13366234	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-329158	usd
CY2023	us-gaap	Investment Income Net InvestmentIncomeNet	1157625	usd
CY2022	us-gaap	Investment Income Net InvestmentIncomeNet	453356	usd
CY2023	us-gaap	Interest Expense InterestExpense	197080	usd
CY2022	us-gaap	Interest Expense InterestExpense	5028618	usd
CY2023	us-gaap	Other Income OtherIncome	-396319	usd
CY2022	us-gaap	Other Income OtherIncome	1801	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	235068	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-12543695	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-20795362	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-37465260	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1280385	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1567026	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-19514977	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-35898234	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.16
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.16
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-5.03
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-5.03
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	9045320	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	9045320	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7142970	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7142970	shares
CY2023	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	-431801	usd
CY2022	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	-49222	usd
CY2023	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-397499	usd
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-14754	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-19480675	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-35898234	usd
CY2023	us-gaap	Depreciation Depreciation	248154	usd
CY2022	us-gaap	Depreciation Depreciation	196510	usd
CY2023	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	471851	usd
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	535119	usd
CY2022	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	500000	usd
CY2023	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-34302	usd
CY2022	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-34468	usd
CY2022	IMNN	Gain Loss From Change In Earnout Milestone Liability GainLossFromChangeInEarnoutMilestoneLiability	5396000	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-329158	usd
CY2023	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	375000	usd
CY2022	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	13366234	usd
CY2023	IMNN	Amortization Of Deferred Finance Charges And Debt Discount Associated With Note Payable AmortizationOfDeferredFinanceChargesAndDebtDiscountAssociatedWithNotePayable	55122	usd
CY2022	IMNN	Amortization Of Deferred Finance Charges And Debt Discount Associated With Note Payable AmortizationOfDeferredFinanceChargesAndDebtDiscountAssociatedWithNotePayable	181259	usd
CY2023	us-gaap	Increase Decrease In Accrued Investment Income Receivable IncreaseDecreaseInAccruedInvestmentIncomeReceivable	-68136	usd
CY2022	us-gaap	Increase Decrease In Accrued Investment Income Receivable IncreaseDecreaseInAccruedInvestmentIncomeReceivable	20088	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	141619	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-43980	usd
CY2022	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	241511	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-1992929	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	2111901	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-19022148	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-23096895	usd
CY2023	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	13541806	usd
CY2022	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	48226390	usd
CY2023	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	25000000	usd
CY2022	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	56775000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	451759	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	267800	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	11006435	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	8280810	usd
CY2022	us-gaap	Proceeds From Issuance Of Redeemable Convertible Preferred Stock ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock	28500000	usd
CY2022	us-gaap	Payments For Repurchase Of Redeemable Convertible Preferred Stock PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock	28500000	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2781438	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	6722654	usd
CY2023	IMNN	Paymentoff Of Loan And Accrued Endofterm Fees PaymentoffOfLoanAndAccruedEndoftermFees	6420000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-3638562	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6722654	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-11654275	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-8093431	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	17492841	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	25586272	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	5838566	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	17492841	usd
CY2023	us-gaap	Income Taxes Paid IncomeTaxesPaid	2500	usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid	2000	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	179542	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	4847359	usd
CY2023	IMNN	Recognition Of Right Use Asset And Liability RecognitionOfRightUseAssetAndLiability	1911049	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	29327866	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-19514977	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	2781438	usd
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	595	usd
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	34302	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	758418	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	13387642	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	55795931	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	55795931	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-35898234	usd
CY2022	IMNN	Stock Issued During Period Value Issuance Of Preferred Stock Upon Financing StockIssuedDuringPeriodValueIssuanceOfPreferredStockUponFinancing	28500000	usd
CY2022	us-gaap	Stock Redeemed Or Called During Period Value StockRedeemedOrCalledDuringPeriodValue	-28500000	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	6722654	usd
CY2022	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	13	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	34468	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2673034	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	29327866	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	29327866	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84A_eus-gaap--UseOfEstimates_zs1Te3mJdYQj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86D_zRwQr3E0IeR9">Use of Estimates</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Financial Statements and the reported amounts of expenses during the reporting period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On an ongoing basis, the Company evaluates its estimates using historical experience and other factors, including the current economic environment. Significant items subject to such estimates are assumptions used for purposes of determining stock-based compensation, the fair value of the earn-out milestone liabilities, estimates for contingent liabilities, if any, and accounting for impairment of in-process research and development assets. Management believes its estimates to be reasonable under the circumstances. Actual results could differ significantly from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p>
CY2023	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0	usd
CY2022	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0	usd
CY2023Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	0	usd
CY2022Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	0	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	248000	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	197000	usd
CY2023	IMNN	Number Of Shares Of Common Stock Issuable Upon Exercise Of Warrants And Equity Awards NumberOfSharesOfCommonStockIssuableUponExerciseOfWarrantsAndEquityAwards	1255642	shares
CY2022	IMNN	Number Of Shares Of Common Stock Issuable Upon Exercise Of Warrants And Equity Awards NumberOfSharesOfCommonStockIssuableUponExerciseOfWarrantsAndEquityAwards	988389	shares
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-19500000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-19000000.0	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-388000000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	15700000	usd
CY2023	IMNN	Proceeds From Sale Of Net Operating Losses ProceedsFromSaleOfNetOperatingLosses	1300000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	9857087	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	21254485	usd
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments	9796291	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	9857087	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	21227991	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	21254485	usd
CY2023Q4	IMNN	Debt Securities Availableforsale Maturity Allocated And Single Maturity Date Rolling Within Three Months Amortized Cost DebtSecuritiesAvailableforsaleMaturityAllocatedAndSingleMaturityDateRollingWithinThreeMonthsAmortizedCost	2467518	usd
CY2023Q4	IMNN	Debt Securities Availableforsale Maturity Allocated And Single Maturity Date Rolling Within Three Months Fair Value DebtSecuritiesAvailableforsaleMaturityAllocatedAndSingleMaturityDateRollingWithinThreeMonthsFairValue	2490775	usd
CY2022Q4	IMNN	Debt Securities Availableforsale Maturity Allocated And Single Maturity Date Rolling Within Three Months Amortized Cost DebtSecuritiesAvailableforsaleMaturityAllocatedAndSingleMaturityDateRollingWithinThreeMonthsAmortizedCost	4005559	usd
CY2022Q4	IMNN	Debt Securities Availableforsale Maturity Allocated And Single Maturity Date Rolling Within Three Months Fair Value DebtSecuritiesAvailableforsaleMaturityAllocatedAndSingleMaturityDateRollingWithinThreeMonthsFairValue	3994590	usd
CY2023Q4	IMNN	Debt Securities Availableforsale Maturity Allocated And Single Maturity Date Rolling Between Three And Twelve Months Amortized Cost DebtSecuritiesAvailableforsaleMaturityAllocatedAndSingleMaturityDateRollingBetweenThreeAndTwelveMonthsAmortizedCost	7328773	usd
CY2023Q4	IMNN	Debt Securities Availableforsale Maturity Allocated And Single Maturity Date Rolling Between Three And Twelve Months Fair Value DebtSecuritiesAvailableforsaleMaturityAllocatedAndSingleMaturityDateRollingBetweenThreeAndTwelveMonthsFairValue	7366312	usd
CY2022Q4	IMNN	Debt Securities Availableforsale Maturity Allocated And Single Maturity Date Rolling Between Three And Twelve Months Amortized Cost DebtSecuritiesAvailableforsaleMaturityAllocatedAndSingleMaturityDateRollingBetweenThreeAndTwelveMonthsAmortizedCost	17222432	usd
CY2022Q4	IMNN	Debt Securities Availableforsale Maturity Allocated And Single Maturity Date Rolling Between Three And Twelve Months Fair Value DebtSecuritiesAvailableforsaleMaturityAllocatedAndSingleMaturityDateRollingBetweenThreeAndTwelveMonthsFairValue	17259895	usd
CY2023Q4	IMNN	Available For Sale Debt Securities Amortized Cost Basis Current AvailableForSaleDebtSecuritiesAmortizedCostBasisCurrent	9796291	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities Single Maturity Date AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate	9857087	usd
CY2022Q4	IMNN	Available For Sale Debt Securities Amortized Cost Basis Current AvailableForSaleDebtSecuritiesAmortizedCostBasisCurrent	21227991	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities Single Maturity Date AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate	21254485	usd
CY2023Q4	IMNN	Available For Sale Securities Unrealized Gains Fair Value AvailableForSaleSecuritiesUnrealizedGainsFairValue	9857087	usd
CY2023Q4	IMNN	Available For Sale Securities Unrealized Holding Gains Less Than Twelve Months AvailableForSaleSecuritiesUnrealizedHoldingGainsLessThanTwelveMonths	60796	usd
CY2022Q4	IMNN	Available For Sale Securities Unrealized Gains Fair Value AvailableForSaleSecuritiesUnrealizedGainsFairValue	13278505	usd
CY2022Q4	IMNN	Available For Sale Securities Unrealized Holding Gains Less Than Twelve Months AvailableForSaleSecuritiesUnrealizedHoldingGainsLessThanTwelveMonths	43508	usd
CY2022Q4	IMNN	Available For Sale Securities Unrealized Loss Fair Value AvailableForSaleSecuritiesUnrealizedLossFairValue	7975980	usd
CY2022Q4	IMNN	Available For Sale Securities Unrealized Holding Losses Less Than Twelve Months AvailableForSaleSecuritiesUnrealizedHoldingLossesLessThanTwelveMonths	-17014	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	9857087	usd
CY2023Q4	IMNN	Available For Sale Securities Unrealized Holding Gains Losses Less Than Twelve Months AvailableForSaleSecuritiesUnrealizedHoldingGainsLossesLessThanTwelveMonths	60796	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	21254485	usd
CY2022Q4	IMNN	Available For Sale Securities Unrealized Holding Gains Losses Less Than Twelve Months AvailableForSaleSecuritiesUnrealizedHoldingGainsLossesLessThanTwelveMonths	26494	usd
CY2023	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	725824	usd
CY2022	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	502578	usd
CY2023	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	431801	usd
CY2022	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	-49222	usd
CY2023	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	431801	usd
CY2022	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	-49222	usd
CY2023	us-gaap	Investment Income Net InvestmentIncomeNet	1157625	usd
CY2022	us-gaap	Investment Income Net InvestmentIncomeNet	453356	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5838566	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11492841	usd
CY2022Q4	us-gaap	Restricted Investments RestrictedInvestments	6000000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5838566	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	17492841	usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	1481	shares
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2854178	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3192063	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2102272	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2643762	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	751906	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	548301	usd
CY2023Q4	us-gaap	Contractual Obligation ContractualObligation	1442659	usd
CY2022Q4	us-gaap	Contractual Obligation ContractualObligation	2196711	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1693383	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2139927	usd
CY2022Q4	us-gaap	Interest Payable Current InterestPayableCurrent	37583	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	234479	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	215402	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	20000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	205313	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3390521	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4794936	usd
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-1280385	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-1567026	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1280385	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1567026	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.071	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.071	pure
CY2023	IMNN	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	-0.031	pure
CY2022	IMNN	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	0.298	pure
CY2023	IMNN	Effective Income Tax Rate Reconciliation Time Up EffectiveIncomeTaxRateReconciliationTimeUp	-1.050	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.029	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.890	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.538	pure
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.061	pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.041	pure
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	12.36
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	67310000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	79800000	usd
CY2023Q4	IMNN	Deferred Tax Assets Legal Act DeferredTaxAssetsLegalAct	4929000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	2016000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	13287000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	74255000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	93087000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	72974615	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	91519974	usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	1280385	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	1567026	usd
CY2023	IMNN	Net Operating Losses Expiration Description NetOperatingLossesExpirationDescription	expire starting in 2029 through 2042
CY2023	us-gaap	Income Tax Examination Description IncomeTaxExaminationDescription	Expenses incurred in connection with R&E activities in the US must be amortized over a 5-year period if incurred, and R&E expenses incurred outside the US must be amortized over a 15-year period. R&E activities are broader in scope than qualified research activities considered under IRC Section 41 (relating to the research tax credit). For the year ended December 31, 2023, the Company performed an analysis based on available guidance and determined that it will continue to be in a loss position even after the required capitalization and amortization of its R&E expenses. The Company will continue to monitor this issue for future developments, but it does not expect R&E capitalization and amortization to require it to pay cash taxes now or in the near future.The Company’s income tax returns for 2019 to 2022 are still open and subject to audit. In addition, net operating losses arising from prior years are also subject to examination at the time they are utilized in future years
CY2023	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	On February 28, 2022, the Company effected a 15-for-1 reverse stock split of its common stock which was made effective for trading purposes as of the commencement of trading on March 31, 2022. As of that date, each 15 shares of issued and outstanding common stock and equivalents was consolidated into one share of common stock. All shares have been restated to reflect the effects of the 15-for-1 reverse stock split. In addition, at the market open on March 1, 2022, the Company’s common stock started trading under a new CUSIP number 15117N602 although the Company’s ticker symbol, CLSN, remained unchanged.
CY2023	us-gaap	Stockholders Equity Note Changes In Capital Structure Retroactive Impact StockholdersEquityNoteChangesInCapitalStructureRetroactiveImpact	To continue listing on The NASDAQ Capital Market, which requires that the Company comply with the applicable listing requirements under NASDAQ Marketplace Rules, which requirements include, among others, a minimum bid price of at least $1.00 per share. On December 2, 2021, the Company received a letter from NASDAQ indicating that the closing bid price of the Company’s common stock fell below $1.00 per share for the previous 30 consecutive business days, and that the Company was therefore not in compliance with the minimum bid price requirement for continued inclusion on The NASDAQ Capital Market. The Company had 180 calendar days, until May 31, 2022, to regain compliance with this requirement, which occurs when the closing bid price of the Company’s common stock is at least $1.00 per share for a minimum of ten consecutive business days during the 180-day compliance period.
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	86557736	shares
CY2023	us-gaap	Stock Issued During Period Shares Reverse Stock Splits StockIssuedDuringPeriodSharesReverseStockSplits	5770516	shares
CY2022Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	300
CY2022Q1	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	28500000	usd
CY2022Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	300
CY2023	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	1000000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	69650	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.92
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	1381	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	12.04
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	100	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	9.45
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	69650	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	1.92
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	22100	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.92
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	59450	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	1.91
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	200	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	4.60
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	32100	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	1.23
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1063482	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	453766	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0339	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0481	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0174	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0397	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	1.000	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.136	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	1.000	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.139	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000	pure
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	400000	usd
CY2023	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y9M18D
CY2021Q4	IMNN	Earnout Milestone Liability EarnoutMilestoneLiability	5396000	usd
CY2022	IMNN	Gain Loss From Change In Fair Value Of Earn Out Milestone Liability GainLossFromChangeInFairValueOfEarnOutMilestoneLiability	5396000	usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	175792	shares
CY2021Q4	IMNN	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice	20.96
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations	7273	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	48.30
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	168519	shares
CY2022Q4	IMNN	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice	19.78
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations	8459	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	37.29
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	160060	shares
CY2023Q4	IMNN	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice	18.86
CY2023	IMNN	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2	P2Y2M12D
CY2023	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.03	pure
CY2023	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Amount DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount	142000	usd
CY2022	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Amount DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount	117000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P24M
CY2023Q1	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P60M
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	626323	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	543009	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	362976	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	370236	usd
CY2023Q4	IMNN	Lessee Operating Lease Liability Payments Due Year Five After Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAfterYearFour	30903	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1933447	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	308733	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1624714	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y6M
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0998	pure
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	646633	usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	644593	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	587744	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	601495	usd
CY2023	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	472000	usd
CY2022	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	535000	usd

Files In Submission

Name	View Source	Status
0001493152-24-011616-index-headers.html	Edgar Link	pending
0001493152-24-011616-index.html	Edgar Link	pending
0001493152-24-011616.txt	Edgar Link	pending
0001493152-24-011616-xbrl.zip	Edgar Link	pending
ex-97.htm	Edgar Link	pending
ex21-1.htm	Edgar Link	pending
ex23-1.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
imnn-20231231.xsd	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
imnn-20231231_pre.xml	Edgar Link	unprocessable
form10-k_htm.xml	Edgar Link	completed
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
imnn-20231231_cal.xml	Edgar Link	unprocessable
imnn-20231231_def.xml	Edgar Link	unprocessable
imnn-20231231_lab.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$IMNN
Imunon, Inc. Stock $imnn

2024 Q1 Form 10-K Financial Statement

#000149315224011616 Filed on March 28, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IMNN Imunon, Inc. Stock $imnn

2024 Q1 Form 10-K Financial Statement

#000149315224011616 Filed on March 28, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IMNN
Imunon, Inc. Stock $imnn